Matthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.

EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.